New study explores combining cancer and blood vessel surgery for advanced gynecologic tumors
NCT ID NCT07267780
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well patients do after surgery that removes both advanced gynecologic cancers and the major blood vessels they have grown into. Researchers will track 130 participants for up to 5 years to see survival rates and how long it takes for the cancer to return. The goal is to gather information to help guide future treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 130 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2035
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The target population of the study consists of patients with advanced or recurrent gynecologic cancers involving major blood vessels by continuity or contiguity, who undergo en bloc tumor resection with simultaneous vascular resection and reconstruction during surgery for disease management.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- Retrospective Arm: 1. Diagnosis of advanced or recurrent gynecologic cancer with vascular involvement requiring resection and/or reconstruction of major blood vessels, including: * Ovarian carcinoma * Cervical carcinoma * Endometrial carcinoma * Vulvar carcinoma * Uterine or other types of sarcomas with vascular involvement 2. Documented major vascular invasion, confirmed by preoperative imaging or intraoperative description. 3. Patients who underwent onco-vascular surgery for advanced or recurrent gynecologic cancers between January 1, 2017, and August 31, 2025. 4. Data Protection Impact Assessment (DPIA) approved for the management of retrospective data. (Deceased or untraceable patients will also be included to avoid selection bias, in accordance with Article 110 bis, paragraph 4 of the Italian Privacy Code. A DPIA will be produced and published on the Sponsor's website before study initiation, and patients who explicitly objected before death will not be included.) Prospective Arm: 1. Age ≥18 years 2. Patients eligible for onco-vascular surgery for advanced or recurrent gynecologic cancers with vascular involvement, including: * Ovarian carcinoma * Cervical carcinoma * Endometrial carcinoma * Vulvar carcinoma * Uterine or other types of sarcomas 3. Documented major vascular invasion, confirmed by preoperative imaging or intraoperative description. 4. Signed informed consent. Exclusion Criteria: 1. Patients younger than 18 years of age 2. Patients with early-stage gynecologic cancers not eligible for onco-vascular surgery 3. Patients undergoing vascular resection due to accidental injury of blood vessels not directly related to tumor infiltration. 4. Patients who have previously undergone vascular surgery for reasons unrelated to the study, to avoid data overlap.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
A.R.N.A.S. Ospedali Civico Di Cristina Benfratell
Palermo, Italy, Italy
-
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, Campania, 80131, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody aims to preserve immune checkpoint while fighting cancer
- Blood test aims to catch Cancer's return earlier
- Blood vessel cells in a simple blood test may predict ovarian cancer therapy success
- Can fewer, stronger radiation doses spare the bowel in gynecologic cancers?
- Can one surgery treat endometrial cancer and obesity together?
- A chill pill for Chemo's side effects? cooling therapy and a Blood-Flow drug take on nerve pain